B Cell Epitope-Based Vaccination Therapy
AbstractCurrently, many peptide vaccines are undergoing clinical studies. Most of these vaccines were developed to activate cytotoxic T cells; however, the response is not robust. Unlike vaccines, anti-cancer antibodies based on passive immunity have been approved as a standard treatment. Since passive immunity is more effective in tumor treatment, the evidence suggests that limited B cell epitope-based peptide vaccines may have similar activity. Nevertheless, such peptide vaccines have not been intensively developed primarily because humoral immunity is thought to be preferable to cancer progression. B cells secrete cytokines, which suppress immune functions. This review discusses the possibility of therapeutic antibody induction by a peptide vaccine and the role of active and passive B cell immunity in cancer patients. We also discuss the use of humanized mice as a pre-clinical model. The necessity of a better understanding of the activity of B cells in cancer is also discussed. View Full-Text
Share & Cite This Article
Kametani, Y.; Miyamoto, A.; Tsuda, B.; Tokuda, Y. B Cell Epitope-Based Vaccination Therapy. Antibodies 2015, 4, 225-239.
Kametani Y, Miyamoto A, Tsuda B, Tokuda Y. B Cell Epitope-Based Vaccination Therapy. Antibodies. 2015; 4(3):225-239.Chicago/Turabian Style
Kametani, Yoshie; Miyamoto, Asuka; Tsuda, Banri; Tokuda, Yutaka. 2015. "B Cell Epitope-Based Vaccination Therapy." Antibodies 4, no. 3: 225-239.